Vesselon
Aug 08, 2019
NMPA approves ALS treatment Edavarone; GSK ends development of Ebola vaccines; Vesselon Acquires FDA-Approved Imagent
Vesselon Acquires FDA-Approved lipid microsphere drug Imagent Vesselon, an oncology therapeutics company, today acquired an FDA-approved drug Imagent for diagnostic purposes as a contrast agent for diagnostic ultrasound. Vesselon’s Vascular Encapsulation Sonication Targeting (VESTTM) system incorporates three FD...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
